Vesicare - Oral Selective Muscarinic Receptor Antagonist for Overactive Bladder (OAB)
Key Data:
Drug (brand / generic)
Vesicare® (solifenacin succinate; YM905)
Company / licensee
Yamanouchi Pharmaceutical Co
Therapy class
Selective anticholinergic
Product description
Oral selective muscarinic receptor antagonist
Current indication
Urinary frequency, urgency and incontinence associated with OAB
Market sector
Urology
Development status
Launched in Europe and the US
